Immix Biopharma (IMMX) Cash from Investing Activities (2021 - 2026)

Immix Biopharma has reported Cash from Investing Activities for 5 years, with the latest figure at -$4.8 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 6989.98% year-over-year to -$4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.9 million (down 1166.26% YoY) and the FY2025 annual result came in at -$7.2 million, down 512.54% from the prior year.
• Cash from Investing Activities advanced to -$4.8 million in Q1 2026 per IMMX's latest filing, from -$6.6 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at -$13177.0 in Q4 2023 and troughed at -$6.6 million in Q4 2025.
• A 4-year average of -$1.3 million and a median of -$286727.5 in 2024 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2025 and 2026: Cash from Investing Activities surged 77.57% in 2025, then sank 6989.98% in 2026.
• Over 4 years, Cash from Investing Activities stood at -$13177.0 in 2023, then plunged by 3748.76% to -$507151.0 in 2024, then slumped by 1210.46% to -$6.6 million in 2025, then increased by 27.76% to -$4.8 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$4.8 million, -$6.6 million, and -$372456.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.